These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38429922)

  • 1. Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
    Kwiatkowski JL; Thompson AA; Tricta F; Temin NT; Rozova A; Fradette C; Badawy SM
    Am J Hematol; 2024 Jun; 99(6):1031-1039. PubMed ID: 38429922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
    Hamdy M; El-Beshlawy A; Veríssimo MPA; Kanter J; Inusa B; Williams S; Lee D; Temin NT; Fradette C; Tricta F; Ebeid FSE; Kwiatkowski JL; Elalfy MS
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30711. PubMed ID: 37807937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
    Soulières D; Mercier-Ross J; Fradette C; Rozova A; Tsang YC; Tricta F
    Ann Hematol; 2022 Mar; 101(3):533-539. PubMed ID: 34981144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
    Kwiatkowski JL; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Alshehri A; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Tricta F; Elalfy MS
    Blood Adv; 2022 Feb; 6(4):1243-1254. PubMed ID: 34847228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
    Elalfy MS; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Fradette C; Rozova A; Temin NT; Tricta F; Kwiatkowski JL
    Blood Adv; 2023 Feb; 7(4):611-619. PubMed ID: 36018224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
    Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
    Paediatr Int Child Health; 2016 Aug; 36(3):209-13. PubMed ID: 26052612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Deferiprone in Iron Chelation.
    Hider RC; Hoffbrand AV
    N Engl J Med; 2018 Nov; 379(22):2140-2150. PubMed ID: 30485781
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
    Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
    Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.